Gang Zeng

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng, Qianhui Wu, Hongxing Pan et al. · The Lancet Infectious Diseases · 2021 · 284 citations · Full text

Vaccination, Vaccine Safety, Coronary Unit +8

Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile

Susan M. Bueno, Katia Abarca, Pablo A. González et al. · Clinical Infectious Diseases · 2021 · 109 citations · Full text

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · 2020 · 95 citations · Full text

Placebo-controlled Phase 2, Immunology, Vaccine Hesitancy +18

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine

Felipe Melo-González, Jorge A. Soto, Liliana A González et al. · Frontiers in Immunology · 2021 · 80 citations · Full text